Observational studyRenal failure2026
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
Observational study in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common complication after cardiac surgery and is associated with increased mortality. Amino acids may improve renal perfusion, but their effect in patients undergoing aortic surgery remains unclear. We used the Aortic Surgery Database of the Shanghai Hospital Development Center to emulate a target trial. Patients were classified to one of two exposure strategies: receiving a daily amino acid dose of > 21 g during the first 2 postoperative days, or not receiving amino acid therapy above this threshold. Overlap weighting was used to balance covariates and emulate randomized assignment. The primary outcome was the incidence of AKI. Secondary outcomes included AKI stage, renal replacement therapy, hospital stay, in-hospital mortality, and 30-day mortality. Overall, 1,816 patients were included in the study. The incidence of AKI and 30-day mortality was 37.8% (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.